Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*
- 1 July 2001
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 68 (2) , 171-179
- https://doi.org/10.1023/a:1011945623464
Abstract
Purpose.To investigate the activity of the combination of gemcitabine (G) plus epirubicin (E) and taxol (T), (GET), in metastatic breast cancer, to evaluate the feasibility of this regimen as...Keywords
This publication has 25 references indexed in Scilit:
- Cardiotoxicity of Epirubicin/Paclitaxel–Containing Regimens: Role of Cardiac Risk FactorsJournal of Clinical Oncology, 1999
- Gemcitabine and Paclitaxel: Pharmacokinetic and Pharmacodynamic Interactions in Patients With Non–Small-Cell Lung CancerJournal of Clinical Oncology, 1999
- An Improved HPLC Method for Therapeutic Drug Monitoring of Daunorubicin, Idarubicin, Doxorubicin, Epirubicin, and Their 13-Dihydro Metabolites in Human PlasmaTherapeutic Drug Monitoring, 1999
- 5-Year Results of Dose-Intensive Sequential Adjuvant Chemotherapy for Women With High-Risk Node-Positive Breast Cancer: A Phase II StudyJournal of Clinical Oncology, 1999
- Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.Clinical Pharmacokinetics, 1999
- Gemcitabine—a safety reviewAnti-Cancer Drugs, 1998
- Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxelAnnals of Oncology, 1996
- Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxicAnnals of Oncology, 1996
- Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.Journal of Clinical Investigation, 1995
- Reporting results of cancer treatmentCancer, 1981